Literature DB >> 17098231

B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.

Suchita Hodawadekar1, Duonan Yu, Diana Cozma, Bruce Freedman, Oriol Sunyer, Michael L Atchison, Andrei Thomas-Tikhonenko.   

Abstract

In mice, zygotic or pro-B-cell-specific knock-out of the Pax5 gene allows differentiation of pro-B-cells into all hematopoietic lineages. We previously generated and characterized a murine B-cell lymphoma, dubbed Myc5, whose cells spontaneously lose Pax5 expression when cultured in vitro, but regain it when re-injected into syngeneic mice. In cultured Myc5 cells, the loss of Pax5 correlates with the acquisition of myeloid markers, such as CD11b and F4/80. Here, we sought to determine whether these cells are truly B-macrophage-restricted or, like Pax5-null progenitors, can give rise to additional hematopoietic lineages. In vitro differentiation assays with various cytokines showed that Myc5 cells do not differentiate into NK cells, dendritic cells, neutrophils, or osteoclasts. At the same time, in the presence of macrophage colony-stimulating factor (M-CSF), they readily phagocytose latex beads and provide T-cell help. Both phenomena are indicative of the bona fide macrophage phenotype. Conversely, enforced Pax5 re-expression in macrophage-like Myc5 cells led to down-regulation of the M-CSF receptor and re-acquisition of some B-cell surface markers (e.g., CD79a) and lineage-specific transcription factors (e.g., IRF4 and Blimp). Retrovirally encoded Pax5 also restored expression of several master B-cell differentiation proteins, such as the IL-7 receptor and transcription factor E2A. In contrast, levels of EBF were unaffected by Pax5 suggesting that EBF acts exclusively upstream of Pax5 and might contribute to Pax5 expression. Indeed, transduction with an EBF-encoding retrovirus partly reactivated endogenous Pax5. Our data reveal the complex relationship between B-cell-specific transcription factors and suggest the existence of numerous feedback mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098231      PMCID: PMC1839943          DOI: 10.1016/j.yexcr.2006.10.015

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  46 in total

1.  Transcription factors in lymphocyte development--T and B cells get together.

Authors:  L H Glimcher; H Singh
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

Review 2.  The B/macrophage cell: an elusive link between CD5+ B lymphocytes and macrophages.

Authors:  M A Borrello; R P Phipps
Journal:  Immunol Today       Date:  1996-10

3.  Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities.

Authors:  S R McKercher; B E Torbett; K L Anderson; G W Henkel; D J Vestal; H Baribault; M Klemsz; A J Feeney; G E Wu; C J Paige; R A Maki
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

4.  Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells.

Authors:  N Rekhtman; F Radparvar; T Evans; A I Skoultchi
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

5.  Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments.

Authors:  S L Nutt; A M Morrison; P Dörfler; A Rolink; M Busslinger
Journal:  EMBO J       Date:  1998-04-15       Impact factor: 11.598

6.  Commitment to the B-lymphoid lineage depends on the transcription factor Pax5.

Authors:  S L Nutt; B Heavey; A G Rolink; M Busslinger
Journal:  Nature       Date:  1999-10-07       Impact factor: 49.962

Review 7.  Essential functions of Pax-5 (BSAP) in pro-B cell development.

Authors:  S L Nutt; C Thévenin; M Busslinger
Journal:  Immunobiology       Date:  1997-12       Impact factor: 3.144

8.  Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1.

Authors:  P Zhang; G Behre; J Pan; A Iwama; N Wara-Aswapati; H S Radomska; P E Auron; D G Tenen; Z Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response.

Authors:  A D Wells; H Gudmundsdottir; L A Turka
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

10.  Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12.

Authors:  B L Kee; C Murre
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

View more
  5 in total

Review 1.  Dissecting teleost B cell differentiation using transcription factors.

Authors:  Patty Zwollo
Journal:  Dev Comp Immunol       Date:  2011-01-17       Impact factor: 3.636

2.  CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Authors:  Elaine Y Chung; James N Psathas; Duonan Yu; Yimei Li; Mitchell J Weiss; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

3.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

4.  c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster.

Authors:  Elaine Y Chung; Michael Dews; Diana Cozma; Duonan Yu; Erik A Wentzel; Tsung-Cheng Chang; Janell M Schelter; Michele A Cleary; Joshua T Mendell; Andrei Thomas-Tikhonenko
Journal:  Cancer Biol Ther       Date:  2008-11-04       Impact factor: 4.742

5.  Increased expression of PcG protein YY1 negatively regulates B cell development while allowing accumulation of myeloid cells and LT-HSC cells.

Authors:  Xuan Pan; Morgan Jones; Jie Jiang; Kristina Zaprazna; Duonan Yu; Warren Pear; Ivan Maillard; Michael L Atchison
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.